/Investor DB

Takeda Ventures — 2022 Investments

5 investments dated 2022 · listed companies and verified rows first · show all

Abintus Bioabintusbio.comAug 2022

BiotechSan Diego, US

Douglas J. Jolly(Founder)inCarlos E. Ibanez(Executive Officer)Robert Anthony Williamson(Director)Troy Wilson(Director)Michael Martin(Director)Nicholas A. Boyle, Ph.D.(Executive Officer, Director)

Co-investorsBioBrit

Code Biotherapeuticscodebiotx.comin𝕏Jun 2022 · $75M

Code Biotherapeutics develops a proprietary non-viral 3DNA delivery platform for genetic medicines, RNAi, and other modalities, using targeting molecules to reach specific cells and tissues outside the liver.

BiotechDeep TechHealthtechHatfield, US

Lauren Kaskiel(Executive Officer)inRobert C. Getts(Executive Officer)Brian McVeigh(Executive Officer, Director)in

BoardDmitry Kuzmin(Director)Victor Stone(Director)Edward Mathers(Director)

Co-investorsNew Enterprise Associates (NEA)4BIO CapitalAmgen VenturesHatteras Venture PartnersJDRF T1D FundNorthpond Ventures+1 more

Enzyreenzyre.comNov 2022

Enzyre develops a handheld diagnostic device that performs multiple blood coagulation assays in parallel to identify bleeding causes at the point of care.

BiotechDeep TechDigital HealthHealthtechMedical DevicesEindhoven, NL

Wim van den Broek(CEO)inWaander(CSO)

Co-investorsi&i Biotech FundNovalis BiotechOost NL

hC Biosciencehcbioscience.comNov 2022Defunct

Cambridge, MA biotech developing engineered tRNA "protein editing" therapeutics for nonsense-mutation diseases; reported shut down in 2025.

Cambridge, US

Leslie J Williams(Executive Officer, Director)

BoardBenjamin Chen(Director)Seiji Miyahara(Director)inSacha Mann(Director)David Moskowitz(Director)Steven Gillis(Director)in

Co-investorsARCH Venture Partners5AM Ventures8VCAtlas VenturePanacea VentureTaiho Ventures, LLC

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

Koneksa Health

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.